window._articleFullText = window._articleFullText || {};
window._articleFullText[2338] = "<div class=\"col-lg-12 col-md-12 col-sm-12 col-xs-12\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t        \t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t        \t\t\t\t<div  style=\"width:100%; float:left;  padding-bottom:0px;\">\n\t\t\t\t\t\t\t\t\t\t\t\t        \t\t\t\t\t<div\tstyle=\"width:100%; float:left; min-height:45px; text-align:justify\">\n\t\t\t\t\t\t\t\t\t\t\t\t        \t\t\t\t\t\t<a href=\"\" name=\"summary_en\"></a>\n\t\t\t\t\t\t\t\t\t\t\t\t        \t\t\t\t\t\t<!--<h2>Summary</h2>-->\n\t\t\t\t\t\t\t\t\t\t\t\t        \t\t\t\t\t\t<p><strong>Background</strong>: Neurofibromatosis type 1 (NF1) is a neurocutaneous disorder that results in a predisposition to the growth of multiple tumors&nbsp;in the central nervous system, the peripheral nervous system, and the skin. The clinical manifestations of neurofibromatosis are associated&nbsp;with loss of neurofibromin expression which causes the upregulation&nbsp;of the RAS pathway. Although neurofibromatosis type 1 can be diagnosed&nbsp;based on the National Institutes of Health criteria, sometimes&nbsp;the diagnosis is difficult, in cases where the characteristic features do&nbsp;not develop. Moreover, other RAS-related disorders may present with&nbsp;significantly overlapping clinical features.<br /><strong>Aims</strong>: To determine the clinical and molecular genetic characteristics&nbsp;of Turkish patients with neurofibromatosis type 1.<br /><strong>Study design</strong>: Cross-sectional study.&nbsp;<br /><strong>Methods</strong>: For the genetic analysis of 27 Turkish families clinically diagnosed&nbsp;with NF1 between 1990 and 2019, we used a multi-step process&nbsp;consisting of next-generation sequencing, multiplex ligation-dependent&nbsp;probe amplification, and array-comparative genomic hybridization.<br /><strong>Results</strong>: In this study, we identified 11 novel and 11 previously reported&nbsp;single-nucleotide variants in 22 families. Whole gene deletions were&nbsp;detected by multiplex ligation-dependent probe amplification analysis&nbsp;in 3 families. Of those, array comparative genomic hybridization analysis&nbsp;defined a 17q11.2 deletion in 4 patients from 2 families and 1.2-Mb&nbsp;involving 1 unrelated patient. All patients with a deletion had facial&nbsp;dysmorphism, suggesting a peculiar phenotype in this group. We could&nbsp;not find any pathogenic variant in the 2 families that met the National&nbsp;Institutes of Health criteria.<br /><strong>Conclusion</strong>: The novel pathogenic variants identified in this study&nbsp;broaden the spectrum of pathogenic variants in NF1 and provide better&nbsp;clinical characterization of NF1. RNA-seq experiments are recommended&nbsp;in patients who meet the National Institutes of Health&nbsp;diagnostic criteria for NF but have not identified any variants in nextgeneration&nbsp;sequencing, multiplex ligation-dependent probe amplification,&nbsp;or array-comparative genomic hybridization analysis.</p>\t\t\t\t\t\t\t\t\t\t\t\t        \t\t\t\t\t</div>\n\t\t\t\t\t\t\t\t\t\t\t\t        \t\t\t\t\t<!--\n\t\t\t\t\t\t\t\t\t\t\t\t        \t\t\t\t\t<div\tstyle=\"width:20%; float:left; min-height:150px; padding:10px; padding-top:40px;\">\n\t\t\t\t\t\t\t\t\t\t\t\t        \t\t\t\t\t\t\t\t\t<a class=\"selected_menu\" href=\"#summary_en\">Summary</a>\t\t\t\t\t\t\t\t\t\t\t\t        \t\t\t\t\t</div>\n\t\t\t\t\t\t\t\t\t\t\t\t        \t\t\t\t\t-->\n\t\t\t\t\t\t\t\t\t\t\t\t        \t\t\t\t</div>\n\t\t\t\t\t\t\t\t\t\t\t\t        \t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t        \t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t        \t\t\t\t\t\t\t\t\t\t\t\t\t\t\t        \t\t\t\n\t\t\n\t\t\t\t\t\t\t\t\t\t\t        \t</div>";
